Showing results (71-80 of 200) with videos related to

Sort By:
Pageof 20
Bulletin Du Cancer|June 10, 2017
[Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center]Carine Ngo, Marick Laé, Julia Ratour, et al.
American Journal of Clinical Oncology|June 19, 2012
Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancerVirginie Marchand, Antoine Angelergues, Vanessa Gobaux, et al.
British Journal of Cancer|February 21, 2018
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
Annals of Surgical Oncology|January 6, 2026
Outcomes of Second Breast-Conserving Surgery Without Reirradiation for Breast Tumor RecurrenceThomas Gaillard, Arnaud Beddok, Yousrah Baadj, et al.
Plos One|August 6, 2016
Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving SurgeryMarie Gosset, Anne-Sophie Hamy, Peter Mallon, et al.
British Journal of Cancer|December 15, 2015
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohortAnne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, et al.
Eclinicalmedicine|January 27, 2025
A reproducible framework for monitoring the impact of randomized clinical trials on clinical practice using large-scale real-world data: application to gynaecological surgical trials using the French national healthcare databaseFloriane Jochum, Madeleine Doll, Anne-Sophie Hamy, et al.
Clinical Pharmacology and Therapeutics|June 16, 2025
Comedications Associated with Immune-Related Adverse Events from Immune-Checkpoint InhibitorsLéonard Laurent, Baptiste Abbar, Kevin Bihan, et al.
Bulletin Du Cancer|February 21, 2025
[Prophylactic breast surgery in high-risk breast cancer patients]Lauren Darrigues, Thomas Gaillard, Jonathan Sabah, et al.
Cancers|January 27, 2021
<i>HER2</i>-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab RegimensEnora Laas, Arnaud Bresset, Jean-Guillaume Féron, et al.
Pageof 20